Biotech Distilled
Substack ↗ Subscribe
Subscribe Substack ↗ About

Home › Therapeutic areas › Hematology

Hematology (20 companies · 12 conditions)

Conditions

Polycythemia Vera 7 Rare AL Amyloidosis 4 Rare Sickle Cell Disease 4 Rare Immune Thrombocytopenia 3 Rare Cold Agglutinin Disease 1 Rare Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy 1 Rare Hemophilia 1 Rare Iron Deficiency Anemia 1 Paroxysmal Nocturnal Hemoglobinuria 1 Rare Pyruvate Kinase Deficiency 1 Rare Systemic Mastocytosis 1 Rare Warm Autoimmune Hemolytic Anemia 1 Rare

Companies

Ticker Company Therapeutic areas In Hematology Lead stage Mkt cap Programs
AGIO Agios Pharmaceuticals HematologyMetabolic Rare 4 Approved $1.76B 7
AKBA Akebia Therapeutics HematologyOphthalmology+2 Rare 1 Approved $111M 10
ANTX AN2 Therapeutics HematologyInfectious Disease+1 Rare 1 Phase 2 $151M 6
ANNX Annexon HematologyNeurology+2 Rare 1 Phase 3 $796M 6
AUTL Autolus Therapeutics HematologyImmunology+3 Rare 1 Approved $341M 12
BEAM Beam Therapeutics HematologyMetabolic+1 Rare 1 Phase 2 $2.73B 6
CLYM Climb Bio HematologyImmunology+1 Rare 1 Phase 2 $604M 8
COGT Cogent Biosciences HematologyOncology Rare 2 NDA Submitted $5.51B 7
CGEM Cullinan Therapeutics HematologyImmunology+2 Rare 2 NDA Submitted $728M 10
IRON Disc Medicine GI/HepatologyHematology+2 Rare 2 Phase 3 $3.59B 9
FBIO Fortress Biotech DermatologyHematology+3 Rare 1 Approved $61.7M 12
IMMX Immix Biopharma Hematology Rare 1 Phase 1 $577M 1
IONS Ionis Pharmaceuticals CardiovascularHematology+5 Rare 3 Approved $6.55B 29
NVCT Nuvectis Pharma HematologyOncology+1 Rare 1 Phase 3 $719M 9
OMER Omeros HematologyNeurology+2 Rare 1 Approved $1.22B 6
PRLD Prelude Therapeutics HematologyOncology Rare 1 Phase 1 $287M 3
PTGX Protagonist Therapeutics DermatologyHematology+2 Rare 2 Approved $8.62B 12
QURE uniQure HematologyMetabolic+1 Rare 1 Approved $1.52B 4
VNDA Vanda Pharmaceuticals CardiovascularDermatology+6 Rare 1 Approved $231M 27
VTVT vTv Therapeutics HematologyMetabolic+1 Rare 1 Phase 3 $84.4M 9